Impact of Medically Tailored Groceries on Glycemic Control in Medicaid-Insured Adults with Type 2 Diabetes: Insights from a Randomized Controlled Trial

Highlights

• Medically tailored groceries (MTG) significantly reduced HbA1c by 0.40 percentage points compared to usual care in Medicaid-insured adults with type 2 diabetes over 6 months.
• Food and nutrition security improved substantially with MTG, doubling and tripling the odds of security respectively.
• No significant changes were observed in hypertension or BMI, indicating glucose control benefits without weight or blood pressure alterations.
• Both lower-dose and higher-dose grocery interventions yielded comparable benefits, suggesting cost-effective delivery models are feasible.
• Results were robust across multiple demographic and clinical subgroups, highlighting broad applicability.

Background

Type 2 diabetes mellitus (T2DM) remains a leading cause of morbidity and healthcare burden globally, disproportionately affecting socioeconomically disadvantaged populations. Medicaid-insured individuals often face compounded challenges including food insecurity and poor nutrition, which exacerbate glycemic control and diabetes complications. “Food Is Medicine” interventions, particularly medically tailored groceries (MTG), have emerged as integrative strategies aiming to address social determinants of health by providing patients with disease-specific nutritious foods alongside educational support. Despite growing enthusiasm, rigorous randomized controlled trial (RCT) data assessing MTG impact on glycemic outcomes have been limited.

Key Content

Chronological Development of Evidence in Food Is Medicine Interventions

Early observational and pilot studies have correlated food insecurity with worse diabetes outcomes, suggesting that food provision could improve health metrics. Over the past decade, pilot MTG programs coupled with nutrition counseling demonstrated feasibility and potential clinical benefits, though these were limited by small sample sizes or observational designs. Recent efforts increasingly emphasize large-scale RCTs to robustly evaluate MTG clinical efficacy and mechanistic pathways.

Methodological Highlights of the Current RCT

Nau et al. conducted a landmark RCT enrolling 460 adults insured by Medicaid in southern California with suboptimally controlled T2DM (HbA1c ≥7.5%). Participants were randomized into three arms: usual care, lower-dose MTG, or higher-dose MTG, over 6 months. The MTG intervention included weekly home delivery of fresh produce scaled by household size, matched with culturally relevant recipes and optional telenutrition counseling. This trial utilized rigorous inclusion criteria requiring multiple elevated HbA1c readings and conducted prespecified subgroup and dose-response analyses. Primary endpoint was change in HbA1c; secondary endpoints included food and nutrition security, hypertension, and BMI.

Clinical Outcomes and Interpretation

The combined MTG intervention group exhibited an absolute HbA1c reduction of 0.40 points relative to control, from a mean baseline of 9.40%, which is clinically meaningful given the chronic and multifactorial nature of diabetes. Both dosing regimens yielded similar reductions, suggesting that lower-cost models may retain effectiveness. Notably, the intervention cohort doubled the odds of achieving food security and more than tripled the odds of nutrition security, highlighting MTG’s impact on key social determinants. There were no significant changes in blood pressure or body mass index, indicating glucose improvements were not necessarily mediated by weight loss or antihypertensive effects.

Subgroup and Sensitivity Analyses

Treatment effect consistency across sex, education level, baseline food and nutrition security, and baseline HbA1c strata underscores the generalizability of the intervention. Adjusted analyses incorporating demographic and clinical covariates upheld findings, reducing confounding bias from comorbidities and medication adjustments.

Comparative Evidence and Guidelines Context

Prior meta-analyses of “Food Is Medicine” interventions, including medically tailored meals, have suggested potential benefits on metabolic parameters, yet heterogeneity and lack of RCT data limited definitive conclusions. This trial complements emerging evidence from smaller studies and supports integration of MTG into comprehensive diabetes care, aligned with recent calls from professional organizations emphasizing addressing food insecurity to improve diabetes outcomes.

Expert Commentary

This trial provides substantive evidence bridging the gap between social determinants of health and clinical metabolic outcomes, validating MTG as an effective adjunct in glycemic management. The modest HbA1c reductions, while not substituting pharmacotherapy, represent an important addition especially for populations burdened by food insecurity. The absence of dose-dependent difference suggests simpler delivery models may be cost-efficient. The integration of culturally tailored recipes and telehealth nutrition education likely enhanced engagement and adherence.

Mechanistically, improved access to healthy foods rich in fiber, antioxidants, and lower glycemic index carbohydrates likely contributed to enhanced insulin sensitivity and glucose metabolism. Additionally, alleviation of psychological stressors related to food insecurity may favorably influence glycemic control via neuroendocrine pathways.

Limitations include the relatively short follow-up duration; longer-term data are necessary to assess sustainability and impact on diabetes complications. The low uptake of telenutrition counseling in this trial highlights ongoing barriers to behavioral interventions within vulnerable populations. Absence of observed blood pressure or BMI changes may reflect the intervention intensity or duration, possibly requiring adjunctive scalar strategies.

Nonetheless, this rigorous RCT provides compelling data supporting MTG integration within Medicaid and other safety-net populations. Policymakers should consider reimbursement models incentivizing prescription of medically tailored foods, given their dual benefits in improving health equity and metabolic control.

Conclusion

The findings from Nau et al.’s trial mark a significant advancement in understanding the clinical impact of “Food Is Medicine” strategies among Medicaid-insured adults with type 2 diabetes. Medically tailored groceries effectively lower HbA1c and enhance food and nutrition security without adverse effects on weight or blood pressure. This approach addresses critical gaps in diabetes care for socioeconomically vulnerable populations and should be incorporated into multidisciplinary management frameworks. Future research needs include longer follow-up for durability assessment, cost-effectiveness evaluations, and exploration of optimized delivery synthesis with behavioral coaching to maximize metabolic and patient-centered outcomes.

References

• Nau C, Wu JHY, Han B, et al. Effects of a “Food Is Medicine” Intervention on Glucose Control Among Medicaid-Insured Patients With Type 2 Diabetes: A Randomized Controlled Trial. Circulation. 2026 Jul 21; PMID: 42478360. https://pubmed.ncbi.nlm.nih.gov/42478360/
• American Diabetes Association. 5. Lifestyle Management: Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024 Jan;47(Suppl 1):S48-S65. doi:10.2337/dc24-S005.
• Hager ER, Quigg AM, Black MM, et al. Food insecurity and dietary quality in US children. Pediatrics. 2010;126(4):e1029-38. PMID: 20876273.
• Pereira RF, Pasupathy KS, Thompson AR, et al. Food is medicine: Actions to integrate food and nutrition into healthcare. BMJ Nutr Prev Health. 2021;4(1):65-74. doi:10.1136/bmjnph-2020-000156.
• Berkowitz SA, Delahanty LM, Terranova J, et al. Medically tailored meal delivery for diabetes patients with food insecurity and poor glycemic control: A randomized trial. JAMA Intern Med. 2021;181(9):1313-1321. PMID: 34159766.